Lista de obras - Kimberly C Banks - Dominio Público Uruguay

10 rare tumors that warrant a genetics referral.

artículo científico publicado en 2013

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

artículo científico publicado en 2020

Abstract 2509: Analysis of clonal hematopoiesis-associated mutations in the cell-free DNA of advanced cancer patients

scholarly article

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

scientific article published on 11 March 2019

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden

artículo científico publicado en 2017

Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer

artículo científico publicado en 2020

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer

artículo científico publicado en 2016

CBM-13CHARACTERIZATION OF CELL-FREE CIRCULATING TUMOR DNA IN LOW GRADE AND MALIGNANT GLIOMAS.

artículo científico publicado en 2015

COMPREHENSIVE META-ANALYSIS OF CRYPTORCHIDISMTESTIS CANCER ASSOCIATION REVEALS A STRONG SECULAR TREND AND NOTABLE MODIFICATION BY HISTOLOGIC TYPE OF TUMOR

artículo científico publicado en 2008

Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.

artículo científico publicado en 2018

Clinical utility of circulating cell-free DNA in advanced colorectal cancer

artículo científico publicado en 2017

Closing the loop: action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs.

artículo científico publicado en 2012

Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristics

artículo científico publicado en 2012

Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

article

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

artículo científico publicado en 2016

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

artículo científico publicado en 2017

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma

artículo científico publicado en 2017

Evolving perspectives on genetic discrimination in health insurance among health care providers

artículo científico publicado en 2010

Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile

artículo científico publicado en 2017

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing

artículo científico publicado en 2017

Genomic landscape of cell-free DNA in patients with colorectal cancer.

artículo científico publicado en 2017

Genomic profile of advanced breast cancer in circulating tumour DNA

artículo científico publicado en 2021

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing

artículo científico publicado en 2018

Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians

artículo científico publicado en 2008

MALIGNANT POTENTIAL OF THE CRYPTORCHID TESTIS ASSOCIATED WITH BILATERAL OCCURRENCE, PERSISTENT NON-DESCENT, AND ADVANCED AGE AT REPAIR: RESULTS OF A COMPREHENSIVE META-ANALYSIS

artículo científico publicado en 2008

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer

artículo científico publicado en 2018

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

artículo científico publicado en 2019

Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations

artículo científico publicado en 2020

Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.

artículo científico publicado en 2015

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

artículo científico publicado en 2017

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer

artículo científico publicado en 2020

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma

artículo científico publicado en 2018

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

artículo científico

O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations

artículo científico publicado en 2016

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

scientific article published on 26 June 2017

Questions Regarding "CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays".

artículo científico publicado en 2017

Re: Prepubertal Orchiopexy for Cryptorchidism May be Associated With Lower Risk of Testicular Cancer

artículo científico publicado en 2008

Selection criteria for genetic assessment of patients with familial melanoma

artículo científico publicado en 2009

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases

artículo científico publicado en 2020

Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals

artículo científico publicado en 2009

Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

artículo científico publicado en 2018

Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non–Small-Cell Lung Cancer: A Multicenter Case Series

artículo científico publicado en 2018

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary

artículo científico publicado en 2017

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

artículo científico

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

scientific article published on 04 August 2019

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

artículo científico publicado en 2018

Lista de obras de Kimberly C Banks

10 rare tumors that warrant a genetics referral.

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Abstract 2509: Analysis of clonal hematopoiesis-associated mutations in the cell-free DNA of advanced cancer patients

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden

Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer

CBM-13CHARACTERIZATION OF CELL-FREE CIRCULATING TUMOR DNA IN LOW GRADE AND MALIGNANT GLIOMAS.

COMPREHENSIVE META-ANALYSIS OF CRYPTORCHIDISMTESTIS CANCER ASSOCIATION REVEALS A STRONG SECULAR TREND AND NOTABLE MODIFICATION BY HISTOLOGIC TYPE OF TUMOR

Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.

Clinical utility of circulating cell-free DNA in advanced colorectal cancer

Closing the loop: action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs.

Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristics

Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma

Evolving perspectives on genetic discrimination in health insurance among health care providers

Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing

Genomic landscape of cell-free DNA in patients with colorectal cancer.

Genomic profile of advanced breast cancer in circulating tumour DNA

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing

Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians

MALIGNANT POTENTIAL OF THE CRYPTORCHID TESTIS ASSOCIATED WITH BILATERAL OCCURRENCE, PERSISTENT NON-DESCENT, AND ADVANCED AGE AT REPAIR: RESULTS OF A COMPREHENSIVE META-ANALYSIS

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations

Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Questions Regarding "CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays".

Re: Prepubertal Orchiopexy for Cryptorchidism May be Associated With Lower Risk of Testicular Cancer

Selection criteria for genetic assessment of patients with familial melanoma

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases

Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals

Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non–Small-Cell Lung Cancer: A Multicenter Case Series

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies